clinical efficacy of oral administration of metronidazole in the treatment of primary sclerosing cholangitis

clinical efficacy of oral administration of metronidazole in the treatment of primary sclerosing cholangitis - clinical efficacy of oral administration of metronidazole in the treatment of PSC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021411

Enrollment

Registered

2016-04-01

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary sclerosing cholangitis

Interventions

Patients take metronidazole 250mg orally three times day for 3 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with a chronic cholestasis who are diagnosed as PSC with the specific findings by MRCP or ERCP 2. Patients with chronic liver injury or compensated liver cirrhosis (Child Pugh score below 9 point) 3. Presence or absence of the PSC-related colitis does not matter for an entry 4. Patients elder than 16 years old who are consented in writing of the applicant

Exclusion criteria

Exclusion criteria: Patients with a decompensated cirrhosis (Child Pugh score upper 10 point)

Design outcomes

Primary

Measure	Time frame
Serological improvement in the hepatobiliary function (serum ALP and total bilirubin) at 12weeks after the treatment	—

Secondary

Measure	Time frame
Alteration of the intestinal flora during the treatment	—

Countries

Japan

Contacts

Public ContactNobuhiro Nakamoto

Keio University, School of Medicine Division of Gastroenterology and Hepatology

nobuhiro@z2.keio.jp+81-3-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026